Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
36.36
-0.34 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
September 08, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...
Via
StockStory
Topics
Economy
Earnings Scheduled For August 6, 2025
August 06, 2025
Via
Benzinga
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 02, 2025
From
Zenas BioPharma
Via
GlobeNewswire
1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off
August 29, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
August 25, 2025
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.
Via
Benzinga
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
August 25, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Value Stock with Exciting Potential and 2 We Avoid
August 25, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings
August 15, 2025
Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks.
Via
Chartmill
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
August 15, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...
Via
StockStory
Topics
Stocks
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
August 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today
August 12, 2025
Via
Benzinga
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
August 12, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14...
Via
StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
August 10, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Royalty Pharma (RPRX) Q2 Receipts Up 20%
August 06, 2025
Via
The Motley Fool
Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance
August 06, 2025
Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence.
Via
Chartmill
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
August 06, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per...
Via
StockStory
Royalty Pharma Reports Second Quarter 2025 Results
August 06, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
August 04, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.
Via
StockStory
Topics
Government
World Trade
2 Reasons to Watch RPRX and 1 to Stay Cautious
July 30, 2025
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its...
Via
StockStory
Topics
Stocks
3 Profitable Stocks to Research Further
July 28, 2025
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...
Via
StockStory
Topics
Supply Chain
Royalty Pharma Declares Third Quarter 2025 Dividend
July 18, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
July 09, 2025
Via
Benzinga
2 Surging Stocks to Research Further and 1 to Be Wary Of
June 26, 2025
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.